Daptomycin Vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
Staphylococcus Aureus Bacteremia | S. Aureus Bloodstream Infection | S. Aureus...This is an open label randomized controlled trial for patients with methicillin resistant S. aureus (MRSA) bloodstream infection which will directly compare the two most commonly used therapies, vancomycin and daptomycin.
This study is an approved sub-study of The Staphylococcus aureus Network Adaptive Platform (SNAP) trial (NCT05137119)
null
Participation Requirements
-
Sex:
ALL -
Eligible Ages:
18 and up
Participation Criteria
The participant must meet all inclusion and exclusion criteria for the SNAP Platform (NCT05137119) and also the following inclusion and exclusion criteria:
Inclusion Criteria:
* Methicillin-resistant S. aureus bacteremia
Exclusion Criteria:
* Severe allergy or non-severe rash to vancomycin or daptomycin
* Suspected or confirmed MRSA pneumonia
* Known vancomycin minimum inhibitory concentration (MIC) greater than or equal to 2mg/L or daptomycin MIC greater than or equal to 1mg/L
Study Location
Fraser Health Authority (Surrey Memorial Hospital)
Fraser Health Authority (Surrey Memorial Hospital)Surrey, British Columbia
Canada
Contact Study Team
Kevin Afra, MD
McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)
McGill University Health Centre (Royal Victoria Hospital and Montreal General Hospital)Montreal, Quebec
Canada
Contact Study Team
Matthew P. Cheng, MD SM
Todd C Lee, MD MPH FIDSA
Emily G McDonald, MD MSc
- Study Sponsored By
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Participants Required
- More Information
- Study ID:
NCT06637332